Department of Thoracic Surgery, The First People's Hospital of Neijiang, Neijiang Affiliated Hospital of Chongqing Medical University, Neijiang, Sichuan, P.R. China.
PLoS One. 2024 Nov 1;19(11):e0312605. doi: 10.1371/journal.pone.0312605. eCollection 2024.
To explore the association between the systemic immune-inflammation index (SII) score and prognosis in immune checkpoint inhibitor (ICI)-treated patients with lung cancer.
PubMed, EMBASE, Web of Science, and CNKI databases were searched up to August 1, 2024. Progression-free survival (PFS) and overall survival (OS) were the primary outcomes queried. Hazard ratios (HRs) and 95% confidence intervals (CIs) were combined, and subgroup analysis was based on pathological type [non-small cell lung cancer (NSCLC) vs. small-cell lung cancer (SCLC)], lines of ICIs (first-line vs. second- or further-line), and combinations of other therapies (yes vs. no).
Twenty retrospective studies with 2424 participants were included. The pooled results demonstrated that an elevated SII was associated with poorer PFS (HR = 1.82, 95% CI: 1.49-2.21; P < 0.001) and OS (HR = 2.31, 95% CI: 1.73-3.09; P < 0.001) in lung cancer patients receiving ICIs. Subgroup analysis stratified by pathological type, lines of ICIs and combinations of other therapies for PFS and OS further revealed the predictive role of the SII in ICI-treated lung cancer patients.
Based on current evidence the SII is significantly related to prognosis and could serve as a reliable prognostic indicator in lung cancer patients receiving ICIs.
探讨系统免疫炎症指数（SII）评分与肺癌免疫检查点抑制剂（ICI）治疗患者预后的关系。
检索 PubMed、EMBASE、Web of Science 和中国知网（CNKI）数据库，截至 2024 年 8 月 1 日。无进展生存期（PFS）和总生存期（OS）是主要的研究终点。合并风险比（HR）及其 95%置信区间（CI），并基于病理类型[非小细胞肺癌（NSCLC）与小细胞肺癌（SCLC）]、ICI 线数（一线与二线或以上）和其他治疗方法联合进行亚组分析。
纳入 20 项回顾性研究，共 2424 名参与者。汇总结果表明，SII 升高与接受 ICI 治疗的肺癌患者的 PFS（HR = 1.82，95%CI：1.49-2.21；P < 0.001）和 OS（HR = 2.31，95%CI：1.73-3.09；P < 0.001）较差相关。进一步对 PFS 和 OS 按病理类型、ICI 线数和其他治疗方法联合进行的亚组分析显示，SII 在接受 ICI 治疗的肺癌患者中的预测作用。
基于目前的证据，SII 与预后显著相关，可作为接受 ICI 治疗的肺癌患者的可靠预后指标。
